GlobeNewswire

2024-09-02 05:57

Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000 Site Members

WAKE FOREST, N.C. and ADELAIDE, Australia , Sept. 01, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning market-leading CRO for biotechs, announced today that 2,000 clinical sites across North America had joined the Avance Clinical GlobalReady Site Partnership Network.

Avance Clinical CEO, Yvonne Lungershausen said these 2,000 highly qualified sites further enhanced delivery of unprecedented efficiency and effectiveness for our biotech clients during their clinical development.

Tina Schied, Avance Clinical’s US-based Senior Site Specialist said the team has individually reviewed these sites for quality, therapeutic area expertise, advanced processes, and compliance so our clients can be assured of quality, rapid startup, and patient access which are vital elements for a successful clinical program.

“Avance Clinical is highly regarded among US-based biotechs and they now make up more than 80% of our clients. A key factor is we can accelerate their clinical development in the US, Australia and Asia, from preclinical stages through to Phase III,” said Schied.

“This is our GlobalReady program which leverages our unique, streamlined multi-region process. With a global pathway, we can ensure efficiency every step of the way,” she said.

“Biotechs are looking for a partner that can seamlessly help transition rapidly with high-quality data that is readily accepted by the FDA and other regulatory agencies. Our in-house global regulatory affairs team assists biotechs to navigate regulatory complexities with confidence and supports our clients with FDA, EMA and TGA submissions.”

“Avance Clinical is a mid-sized, agile, and responsive CRO with a proven track record of swiftly advancing high-quality clinical programs. Our global team is focussed on accelerating drug development for its biotech clients, from preclinical stages through to Phase III.” 

Avance Clinical is also an accredited cell and gene technology CRO which means it can run clinical operations for pre-clinical and clinical trials for GMO therapies.

New analysis by market research leader Frost & Sullivan shows one of the major challenges for US biotechs was finding the right biotech aligned CRO partner.

“More than 60% of US biotechs experience delays seeking the right CRO partner to accelerate their drug development programs,” Lungershausen said. (See report here).

The comprehensive report underscores the increasing biotech preference to collaborate with the right sized CROs that can accommodate the fast-paced nature of biotech demands.

Find out more:

About Avance Clinical
Avance Clinical is the largest premium full-service Australian, Asian, North American and EU CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that require fast, agile, and adaptive solution-oriented clinical research services.

Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past five years, has been providing CRO services in the region for more than 26 years.

Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right from pre-clinical through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.

With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.

www.avancecro.com


Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson

Primary Logo

source: Avance Clinical

送禮活動浪接浪!想緊貼著數活動消息?即Like etnet Facebook專頁!► 立即讚好

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
4
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
5
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
6
一本萬利 | 2025年的五個「勿」(有片)
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
9
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
10
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
11
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
12
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
13
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
14
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
15
習近平應約與特朗普通電話,特:冀盡快與習見面
16
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
17
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
18
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
19
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
20
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
21
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
22
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
23
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
24
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
25
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
26
特朗普就職 | 特朗普上台後行動列表
27
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
28
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
29
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
30
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老